皮质类固醇在IgA神经病变中的个性化治疗效应
medRxiv : the preprint server for health sciences
|November 24, 2025
概括
皮质类固醇并不能显著改善IgA脏病 (IgAN) 的脏存活率. 然而,一个新的机器学习模型识别了受益的特定患者群体,从而实现了个性化的Igan治疗,并减少了不必要的皮质类固醇使用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 人工智能的人工智能
- 精准医学是一门精准的医学.
背景情况:
- IgA脏病 (IgAN) 是导致功能衰竭的主要原因.
- 在IgAN中对皮质类固醇的治疗反应是可变的,证据是相互矛盾的.
- 由于副作用和异质反应,需要个性化治疗方法.
研究的目的:
- 开发一种因果机器学习框架,以预测IGAN中的个人皮质类固醇治疗效应.
- 整合临床,组织病理学和病理学数据,以进行个性化治疗预测.
- 为了改善Igan患者的治疗策略.
主要方法:
- 开发了一个因果机器学习框架,使用了来自八个国际队列的1,022名患者的数据.
- 综合临床变量,组织病理学得分,以及来自数字化脏活检的基于深度学习的病理学.
- 分析了队列级和分群级治疗对脏存活率的影响.
主要成果:
- 皮质类固醇在队列水平上对五年脏存活率没有显著影响.
- 该框架确定了具有和没有显著的皮质类固醇益处的患者亚群.
- 在响应的子群体中,无进展的存活率有所改善,而在不响应者中,过度治疗减少了.
- 管状间歇性炎症和状形变形通过病理学预测了皮质类固醇反应.
结论:
- 开发的框架通过预测个性化皮质类固醇效应,使IgA脏病的精确治疗成为可能.
- 这种方法支持临床决策,并在新兴疗法背景下优化治疗.
- 个性化治疗策略可以改善治疗结果,减少IgAN的过度治疗.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
417
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
417
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Inflammatory Bowel Disease IV: Pharmacological Management
452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
452
Drugs for Treatment of Ulcerative Colitis in IBD
435
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
435
Nephrotic Syndrome III : Nursing Management
271
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
271


